IDEAYA Biosciences (IDYA) Change in Accured Expenses (2018 - 2026)

IDEAYA Biosciences (IDYA) has 9 years of Change in Accured Expenses data on file, last reported at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 5.15% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $10.3 million (down 31.21% YoY), and the FY2025 full-year result was $10.4 million, down 3.4% from the prior year.
• Change in Accured Expenses advanced to $2.7 million in Q1 2026, from -$4.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.5 million in Q3 2025 to a low of -$4.8 million in Q4 2025.
• A 5-year average of $1.8 million and a median of $2.4 million in 2023 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 668.11% in 2023, while the deepest fall reached 399.29% in 2023.
• Tracing IDYA's Change in Accured Expenses over 5 years: stood at $323000.0 in 2022, then jumped by 668.11% to $2.5 million in 2023, then declined by 8.34% to $2.3 million in 2024, then sank by 311.04% to -$4.8 million in 2025, then surged by 156.82% to $2.7 million in 2026.
• Business Quant data shows IDYA's Change in Accured Expenses at $2.7 million in Q1 2026, -$4.8 million in Q4 2025, and $7.5 million in Q3 2025.